Holen Sie sich die Stockscreener-App
10.65
2.56%
-0.28
Handel nachbörslich:
10.66
0.010
+0.09%
Schlusskurs vom Vortag:
$10.93
Offen:
$10.88
24-Stunden-Volumen:
1.45M
Relative Volume:
0.62
Marktkapitalisierung:
$1.05B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.84M
KGV:
-22.66
EPS:
-0.47
Netto-Cashflow:
$-44.23M
1W Leistung:
+3.10%
1M Leistung:
+6.18%
6M Leistung:
-26.40%
1J Leistung:
-28.76%
1-Tages-Spanne:
$10.64
$11.37
1-Wochen-Bereich:
$10.38
$11.70
52-Wochen-Spanne:
$9.335
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Vergleichen Sie SPRY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
10.65 | 1.12B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Eingeleitet | Roth Capital | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
How ARS Pharmaceuticals Inc. stock trades during market volatilityWeekly Investment Report & Weekly Stock Performance Updates - newser.com
Why ARS Pharmaceuticals Inc. stock could rally in 2025Exit Point & Weekly High Return Opportunities - newser.com
Trend analysis for ARS Pharmaceuticals Inc. this weekDay Trade & Community Consensus Stock Picks - newser.com
Sentiment analysis tools applied to ARS Pharmaceuticals Inc.Earnings Summary Report & AI Enhanced Trading Alerts - newser.com
Is ARS Pharmaceuticals Inc. stock supported by innovation pipelinePortfolio Risk Report & High Return Trade Opportunity Guides - newser.com
Why ARS Pharmaceuticals Inc. stock could outperform in 2025Buy Signal & Fast Exit/Entry Strategy Plans - newser.com
Price action breakdown for ARS Pharmaceuticals Inc.Weekly Trade Summary & Community Consensus Trade Signals - newser.com
Is ARS Pharmaceuticals Inc. a candidate for recovery playPortfolio Gains Summary & Expert Approved Momentum Ideas - newser.com
ARS Pharmaceuticals (SPRY): Assessing Valuation After European Patent Win Secures Neffy Exclusivity Through 2039 - Sahm
How to track smart money flows in ARS Pharmaceuticals Inc.Market Trend Summary & Accurate Trade Setup Notifications - newser.com
ARS Pharmaceuticals (SPRY) Is Up 9.8% After Securing $250M Loan and European Patent Win – Has the Bull Case Changed? - Sahm
Epi Spray Maker Urges FDA to Require More Study of Epi Film - Allergic Living
Pattern recognition hints at ARS Pharmaceuticals Inc. upside2025 Price Momentum & Long-Term Safe Return Strategies - newser.com
Firm Helps Secure Favorable Decision from European Patent Office on Behalf of ARS Pharmaceuticals - Wilson Sonsini
ARS Pharmaceuticals' (SPRY) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
ARS Pharmaceuticals Hits Day High with 7.55% Surge to $11.11 - Markets Mojo
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy - MarketScreener
Asthma Market to Evolve Rapidly Over the Next Decade by 2034, - openPR.com
Firm Advises ARS Pharma on Patent Matters Related to Loan Facility Up to $250 Million - Wilson Sonsini
ARS Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
ARS Pharma’s epinephrine nasal spray patent upheld in Europe By Investing.com - Investing.com Australia
ARS Pharma’s epinephrine nasal spray patent upheld in Europe - Investing.com
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray) - The Manila Times
ARS Pharmaceuticals receives favorable decision from European Patent Office on patent related to neffy (epinephrine nasal spray) - MarketScreener
ARS Pharmaceuticals Receives Favorable Decision from - GlobeNewswire
EP 3678649 Upheld in 30+ Countries: ARS Pharmaceuticals' neffy® patent Secured Through 2039 - Stock Titan
Knights of Columbus Asset Advisors LLC Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
What drives ARS Pharmaceuticals Inc stock priceEmerging Market Stocks & Your Free Entry to Smart Investing Starts Here - earlytimes.in
ARS Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Is ARS Pharmaceuticals Inc. building a consolidation baseWeekly Market Report & Safe Entry Point Identification - newser.com
Using data tools to time your ARS Pharmaceuticals Inc. exit2025 Investor Takeaways & Technical Buy Zone Confirmation - newser.com
How to use Fibonacci retracement on ARS Pharmaceuticals Inc.M&A Rumor & Real-Time Sentiment Analysis - newser.com
Published on: 2025-10-05 03:09:06 - newser.com
Is ARS Pharmaceuticals Inc. stock a buy before product launchesWeekly Trade Recap & Breakout Confirmation Alerts - newser.com
A Look at ARS Pharmaceuticals’s Valuation Following Major $250M Funding for Neffy Commercial Growth - Sahm
ARS Pharmaceuticals (SPRY) Is Up 5.2% After Securing $250M Term Loan to Accelerate Neffy Launch – Has the Bull Case Changed? - Yahoo Finance
Why ARS Pharmaceuticals (SPRY) Is Up 7.8% After Securing $250M Loan and Japan Approval for neffy - Sahm
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating - 富途牛牛
ARS Pharma secures $250M loan to accelerate Neffy rollout - MSN
William Blair Expects Lower Earnings for ARS Pharmaceuticals - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 6.6%Here's Why - MarketBeat
Epinephrine nasal spray maker ARS sues Aptar alleging device supply monopoly - Reuters
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity - citybiz
ARS Pharmaceuticals Locks In $250 Million To Grow Neffy - Finimize
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies - WV News
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):